Seeking Alpha

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit ...
Nasdaq

PTC Inks License And Collaboration Deal With Novartis For PTC518 Huntington's Disease Program

(RTTNews) - Biopharmaceutical company PTC Therapeutics, Inc. (PTCT) announced Monday the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corp., a ...
GEN

Novartis, PTC Ink Up-to-$2.9B Huntington’s Disease Collaboration

Novartis will partner with PTC Therapeutics to expand the use of PTC’s small molecule splicing platform to develop PTC’s PTC518 Huntington’s disease program and an unspecified number of related ...
Seeking Alpha

PTC Therapeutics stock jumps on $2.9B license deal with Novartis for Huntington's disease drug candidate

PTC Therapeutics (NASDAQ:PTCT) shares jumped around 21% Monday morning after it inked an exclusive global license and collaboration agreement with Novartis Pharmaceuticals (NYSE:NVS) for its PTC518 ...